The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic factors of overall survival in head and neck cancer: Post-hoc exploratory results from the SPINNAKER trial—A phase III randomized clinical trial of pemetrexed plus cisplatin versus cisplatin monotherapy.
S. Urba
No relevant relationships to disclose
J. Gatz
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
W. Shen
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
A. Hossain
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
K. Winfree
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
A. Koustenis
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
P. Peterson
Employment or Leadership Position - Lilly
Stock Ownership - Lilly